Conclusion: Transepithelial, or epithelium-on CXL, is progressing in the U.S. in part thanks to CXLUSA’s prospective, non-randomized, multicenter investigation of CXL to treat keratoconus.
Authors
Roy S. Rubinfeld, MD, MA
Conclusion: Transepithelial, or epithelium-on CXL, is progressing in the U.S. in part thanks to CXLUSA’s prospective, non-randomized, multicenter investigation of CXL to treat keratoconus.